Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.

All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical Center
• Treatments: Anticoagulants

Criteria

Inclusion Criteria:

• Patients of age ≥18 years who undergo isolated CABG for coronary artery disease

• POAF that persists for >60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery

Exclusion Criteria:

• Clinical history of either permanent, persistent or paroxysmal atrial fibrillation

• Any pre-existing clinical indication for long-term OAC

• Any absolute contraindication to OAC

• Planned use of post-operative dual antiplatelet therapy (DAPT)

a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent.

• Cardiogenic shock

• Major perioperative complication* occurring between CABG and randomization

a. Including stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade).

• Concomitant left atrial appendage closure during CABG

• Concomitant valve surgery during CABG (including aortic, mitral, tricuspid or pulmonary)

• Concomitant or prior surgery for AF during CABG

• Closure of an atrial septal defect or of a patent foramen ovale during CABG

• Stage IV or V chronic kidney disease (estimated glomerular filtration rate [eGFR]<30 mL/min/1.73m2)

• Liver cirrhosis or Child-Pugh Class C chronic liver disease

• Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial

• Pregnancy at the time of randomization

• Unable or unwilling to provide inform consent

• Unable or unwilling to comply with the study treatment and follow-up

• Existence of underlying disease that limits life expectancy to less than one year